SARS-CoV-2 is the seventh coronavirus that is
reported to cause infection in Homo sapiens. Considering its pandemic nature,
development of newer and effective therapeutic strategies, drug repurposing in
combination with target validation approaches has led to the identification of
new antiviral molecules. In current work, we performed virtual screening and
molecular docking of 8548 ligands on target protein coronavirus
endoribonuclease NendoU (6VWW). The molecules selected includes FDA approved
drugs along with investigational or experimental drugs recommended for anticancer,
antiviral, antimicrobial, and antiprotozoal properties. The thorough selection
and their rationality with Covid-19 led us to propose that FDA approved drug
DB00876 (Eprosartan), Investigational drugs DB15063 (Inarigivir soproxil),
DB12307 (Foretinib) and DB01813 an experimental drug may be repurposed for
treatment of Covid-19 disease.